Fig. 5

ANs overcome cisplatin resistance by restoring intracellular drug accumulation. (A) Schematic illustration of arsenene nanosheets restores the sensitivity of drug-resistant cells to cisplatin. (B) Relative viabilities of U2OS and U2OS/CDDP cells after various treatments (CDDP: 2 µg/mL; As ions: 10 µg/mL). (C, D) Total intracellular Pt content (C) and DNA-binding Pt content (D) in U2OS and U2OS/CDDP cells after incubation with CDDP or Her2-ANs@CDDP (CDDP: 2 µg/mL). (E) The level of GSH in U2OS and U2OS/CDDP cells. (F, G) Flow cytometry analysis of cell death in U2OS/CDDP cells treated with various treatments (CDDP: 2 µg/mL; As ions: 10 µg/mL). (H, I) Flow cytometry analysis of the production of ROS (H) and lipid peroxide (I) in U2OS/CDDP cells after different treatments. (J) Immunofluorescence staining of γH2A.X formation (green fluorescence) in U2OS/CDDP cells after various treatments (CDDP: 2 µg/mL; As ions: 10 µg/mL). Scale bar: 100 μm. (Values are presented as means ± sd, n = 3, *P < 0.05, **P < 0.01.)